



## Product Datasheet

<b>Product Name</b>	Formiminotransferase Cyclodeaminase Human Recombinant
<b>Cata No</b>	CB500479
<b>Source</b>	Sf9 insect cells.
<b>Synonyms</b>	Formiminotransferase-cyclodeaminase, FTCD, LCHC1, LC-1.

### Description

Formiminotransferase cyclodeaminase is an enzyme which catalyzes the conversion of formiminoglutamate and tetrahydrofolate into formiminotetrahydrofolate and glutamate.

Formiminotransferase cyclodeaminase, a bifunctional enzyme of tetrahydrofolate synthesis, is the target antigen of anti-LC1 (liver cytosol antigen type 1) autoantibodies. Presence of LC1 autoantibodies is a marker for type 2 autoimmune hepatitis (for which anti-LKM 1/cytochrome P450 2D6 autoantibodies are a further marker).

Serum LC1 autoantibody concentrations appear to fluctuate in parallel with aminotransferase levels, a particularly intriguing observation that suggests a possible role of LC1 autoreactivity in the pathogenic mechanism leading to hepatocyte injury.

Formiminotransferase Cyclodeaminase Human

Recombinant (also called liver cytosol type 1) produced in SF9, is a glycosylated, polypeptide chain having a molecular mass of 59,749 Dalton. The FTCD is expressed with a -6xHis tag and purified by proprietary chromatographic techniques.

### Purity

Greater than 95% as determined by SDS-PAGE.

### Formulation

FTCD is supplied at a concentration of 0.5mg/ml in 16mM HEPES buffer pH-7.6, 240mM sodium chloride, and 20% glycerol.

### Applications

Western-Blot with monoclonal anti-hexa-His-tag antibody and autoimmune hepatitis (AIH II) patient sera.